Note: the content in these publications is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Feasibility of Neurapheresis™ Therapy for
Multidrug Resistant Gram-negative Bacterial Meningitis
Duke University Medical Center/Minnetronix Neuro
ID Week 2017 – October 4-8, 2017 – San Diego, CA
Pseudomonas, Acinetobacter and Klebsiella are three multidrug resistant (MDR) gram-negative pathogens that pose a threat to human health. Patients in hospitals or nursing homes, and with devices such as intravenous catheters or ventilators are at increased risk of Gram-negative bacterial meningitis (GBM) from these bacteria. GBM manifests when these bacteria invade the central nervous system. Increasingly antibiotic resistant bacteria strains cause high mortality associated with MDR GBM. This poster demonstrates the feasibility of Neurapheresis™ Therapy for MDR GBM, and characterizes system parameters for bacterial, endotoxin, and cytokine clearance.
Minnetronix is a registered trademark, and Neurapheresis is a trademark of Minnetronix, Inc.
©Minnetronix, Inc. All rights reserved.